Immunomodulation by cannabinoids: Current uses, mechanisms, and identification of data gaps to be addressed for additional therapeutic application.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical, clinical, and genetic literature without a systematic review methodology
PubMed 34099105 · doi:10.1016/bs.apha.2021.01.001
What was done
This narrative review synthesized evidence on cannabinoid-based therapeutics (CBTs) targeting CB1 and CB2 receptors in immune-mediated conditions (including multiple sclerosis, inflammatory bowel disease, asthma, arthritis, diabetes, HIV, and HIV-associated neurocognitive disorder). The authors evaluated selected animal models, human randomized trials and meta-analyses, and single nucleotide polymorphism (SNP) genetic studies of the CNR1 and CNR2 genes, while outlining key evidentiary gaps.
What was found
The abstract provides no quantitative data, effect sizes, or trial counts. It qualitatively notes that modulation of endogenous cannabinoid levels or direct targeting of CB1 and CB2 receptors demonstrates anti-inflammatory and immunosuppressive properties across multiple preclinical models and human clinical conditions.
Why it matters
It outlines the mechanistic and preliminary clinical rationale for targeting the endocannabinoid system in autoimmune and inflammatory disorders while highlighting research priorities required to establish risk-benefit profiles.
Limits
The paper is a non-systematic narrative overview with unsystematic study selection, no formal risk-of-bias assessment, and no pooled quantitative analysis. The abstract reports no numerical endpoints or sample sizes.
Cited by
- supports Cannabinoids suppress the immune system and operate primarily through two receptor types: cannabinoid receptor type 1 predominantly on neurons, and cannabinoid receptor type 2 predominantly on immune cells.